A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma

This is a Phase 1, open-label, multi-center study to evaluate the safety of JMT601 in the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma and to determine the recommended dose for Phase 2 studies (RP2D). Study consists of 2 parts. The first part is a dose-escalation part using a 3+3 design with up to 6 dose(0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 12 mg/kg and 20 mg/kg) escalation cohorts at increasing levels. The second part is a dose-expansion part at R2PD dose to assess preliminary efficacy of JMT601.

Trial Details

NCT ID
NCT06725524
Phase
PHASE1
Sponsor
Shanghai JMT-Bio Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • JMT601
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Participants diagnosed with CD20-positive B-cell non-Hodgkin lymphoma confirmed by histopathology and/or cell biology who have previously received …
  • Eastern Cooperative Oncology Group (ECOG) physical state score: 0-2
  • Participants must have at least one evaluable or measurable lesion according to Lugano 2014 criteria.
  • Expected survival of at least 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →